NCT05748119View on ClinicalTrials.gov

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

October 1, 2023

Study Completion Date

October 1, 2023

Conditions
Pain
Interventions
DRUG

MEB-1170

Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

DRUG

Placebo

Equivalent number and size of capsules containing placebo

Trial Locations (1)

32117

RECRUITING

Labcorp Clinical Research Unit, Inc, Daytona Beach

Sponsors
All Listed Sponsors
lead

Mebias Discovery, Inc

INDUSTRY

NCT05748119 - A Study to Assess the Safety of MEB-1170 in Healthy Subjects | Biotech Hunter | Biotech Hunter